arrow
T

Tomasz Rzymski

ryvu therapeutics
H指数:19
被引数:1,893

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma

介导子激酶对蛋白质合成的转录调控代表了MYC驱动的髓母细胞瘤的治疗易损性。

2025-12-160
OA
Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer

整合转录组学和功能建模揭示AKT和mTOR在结直肠癌中的协同作用

2025-07-310
OA
Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

进行中试验:一项开放标签临床试验,评估RVU120作为单药治疗或与Ruxolitinib联用治疗中危或高危、原发性或继发性骨髓纤维化患者的疗效(POTAMI-61)。

BLOOD
IF23.1
2024-11-050
PRE
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses (vol 131, e140752, 2021)
2024-05-010
OAAI
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma (vol 127, pg 4179, 2017)
2024-04-151
OAAI
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses
2021-04-1536
OA
Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock
2021-03-016
PREAI
Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
2020-08-150
PRE
SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia
2019-07-011
PRE
Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors
2018-12-0615
PREAI
CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of various transcriptional programs involved in maintenance of leukemia stem cells
2018-07-010
PRE